Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384639 | 0.93 | ABCB1 (0.66) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL11554662 | 0.92 | LMNA (0.61) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL14901496 | 0.92 | AR (0.62) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL16387655 | 0.92 | AR (0.62) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL16387650 | 0.92 | AR (0.62) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL16387651 | 0.92 | AR (0.62) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL16387652 | 0.92 | AR (0.62) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL12516207 | 0.88 | LMNA (0.49) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL24198673 | 0.87 | PLA2G4B (0.61) | LMNAMAPTPOLBNPSR1ABCB1 | |
| SCHEMBL17908021 | 0.87 | PLA2G4B (0.61) | LMNAMAPTPOLBNPSR1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | LMNA 1050/4885MAPT 1962/4885POLB 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.